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Abstract A unification of doping-control screening proce-
dures of prohibited small molecule substances—including
stimulants, narcotics, steroids, β2-agonists and diuretics—
is highly urgent in order to free resources for new classes
such as banned proteins. Conceptually this may be achieved
by the use of a combination of one gas chromatography–
time-of-flight mass spectrometry method and one liquid
chromatography–time-of-flight mass spectrometry method.
In this work a quantitative screening method using high-
resolution liquid chromatography in combination with
accurate-mass time-of-flight mass spectrometry was devel-
oped and validated for determination of glucocorticosteroids,
β2-agonists, thiazide diuretics, and narcotics and stimulants in
urine. To enable the simultaneous isolation of all the
compounds of interest and the necessary purification of the
resulting extracts, a generic extraction and hydrolysis proce-
dure was combined with a solid-phase extraction modified for
these groups of compounds. All 56 compounds are determined
using positive electrospray ionisation with the exception of the
thiazide diuretics for which the best sensitivity was obtained by
using negative electrospray ionisation. The results show that,
with the exception of clenhexyl, procaterol, and reproterol, all
compounds can be detected below the respective minimum
required performance level and the results for linearity,
repeatability, within-lab reproducibility, and accuracy show
that the method can be used for quantitative screening. If
qualitative screening is sufficient the instrumental analysis may
be limited to positive ionisation, because all analytes including
the thiazides can be detected at the respective minimum
required levels in the positive mode. The results show that the
application of accurate-mass time-of-flight mass spectrometry
in combination with generic extraction and purification
procedures is suitable for unification and expansion of the
window of screening methods of doping laboratories. More-
over, the full-scan accurate-mass data sets obtained still allow
retrospective examination for emerging doping agents, without
re-analyzing the samples.
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Introduction
The task of doping control laboratories is to screen for a wide
range of drugs currently included in the list of prohibited
substances published by the World Anti-Doping Agency
(WADA) [1]. Today, the cost-effectiveness of analytical
procedures is becoming an important issue for all laborato-
ries involved in doping control or residue analysis. A way to
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improve cost-effectiveness is to maximize the number of
analytes that may be determined in a single procedure, e.g. to
use multi-compound techniques. However, most methods are
developed for the determination of specific prohibited com-
pounds or compound groups. Because resources are needed to
determine new classes of doping compounds such as banned
proteins, unification of doping control screening procedures
for prohibited small molecule substances—including stimu-
lants, narcotics, steroids,β2-agonists, and diuretics—is highly
urgent. Conceptually this may be achieved by the use of a
combination of one gas chromatography–time-of-flight mass
spectrometry (GC–TOFMS) method and one liquid chroma-
tography time-of-flight mass spectrometry (LC–TOFMS)
method. The aim of this study is to develop and validate a
multi-compound LC–TOFMSmethod for compounds that are
less suitable for GC–MS methods. Traditionally, capillary gas
chromatography combined with mass spectrometry (GC–MS)
has been used in doping analysis including laborious sample
preparation for analytes or metabolites with a polar, non-
volatile, or thermolabile nature [2]. As an alternative, liquid
chromatography combined with mass spectrometry (LC–MS)
may be used for those targeted molecules in urine that cannot
be covered by standard GC–MS methods. While LC
combined with tandem mass spectrometry (LC–MS–MS)
has excellent sensitivity and selectivity for target analytes in
doping analysis [3–6], true multi-compound analyses
requires a sensitive full-scan MS technique, for example
time-of-flight mass spectrometry (TOFMS) or Orbitrap mass
spectrometry [7–9]. These analyzers provide high specificity
because of both high mass accuracy and high mass
resolution and allow the reconstruction of highly selective
accurate mass chromatograms for a theoretically unlimited
number of compounds in complex matrices. Furthermore,
data can be acquired and reprocessed without any a priori
knowledge about the presence of specific compounds; that
is, no analyte-specific information is required before injecting
a sample and the presence of newly identified compounds can
be confirmed in previously analysed samples simply by
reprocessing the data. The advantage of TOFMS can be
further improved by combining it with high-resolution LC
(HRLC) such as ultra performance LC (UPLC). Recent
research has shown that UPLC–TOFMS has significant
advantages concerning selectivity, sensitivity, and speed
[10–14]. This paper describes the development and valida-
tion of a quantitative screening method based on UPLC–
TOFMS for analysis of 56 restricted substances that are not
very suitable for detection with GC–MS methods, including
corticosteroids, β2-agonists, and diuretics. Corticosteroids
affect the nervous system causing euphoria, alleviate pain,
and enhance the athlete’s ability to concentrate in endurance
or power events [15, 16]. (Gluco)corticosteroids show
extensive metabolism in the human body and are generally
excreted in urine at low concentrations complicating the
analysis of these compounds [17, 18]. Most corticosteroids
are non-volatile, therefore excluding GC–MS analysis of
urine samples unless lengthy derivatization or oxidation
procedures are used prior to GC–MS analysis. Generally,
LC–MS–MS with different ionization techniques has been
used [19–21]. In addition LC–TOFMS has been used for
toxicological drug screening of related compounds [22] and
specifically for doping agents in human urine [23]. The
minimum required performance limit (MRPL) established
for these compounds, at which all laboratories should be able
to perform [24], is 30 ng mL−1 in urine. The structures and
names of the 19 corticosteroids involved in this study are given
in Fig. 1.
β2-Agonists act on the β2 adrenergic receptor, causing
muscle relaxation resulting in a widening of the bronchial
passages and blood vessels in the muscles, thereby
improving the performance of the athletes [25]. β2-
Agonists can be divided into short-acting and long-acting
groups with salbutamol and terbutaline as examples of the
first group and salmeterol and clenbuterol as examples of
the latter group. β2-Agonists, for example salbutamol, have
become a concern in sports, because these drugs, when
used at high doses, can act as anabolic agents to promote
weight, mainly in the form of muscle [26]. As of 2006,
WADA permits the use of selected β2-agonists (salbutamol,
salmeterol, terbutaline, and eformoterol) in athletic competi-
tion only by asthmatic athletics. For salbutamol the threshold
value is 1000 ng mL−1 while for all other β2-agonists the
MRPL is 100 ng mL−1. β2-Agonists in urine have been
analysed using LC–MS–MS [27] and LC–TOFMS [23], but
also LC combined with Orbitrap mass spectrometry [28], in
all cases after hydrolysis and liquid–liquid extraction of the
sample. The structures and names of the 22 β2-agonists
involved in this validation study are given in Fig. 2.
Diuretics increase the urine flow, thereby reducing body
mass and potentially leading to the athlete’s classification in
a lower weight class in some sports. Thiazide diuretics are
also regarded as masking agents, because the increased
urine flow and volume dilute possible residues of sports
doping and for these reasons all diuretics appear on the
prohibited list, both in and out of competition with an
MRPL of 250 ng mL−1. Diuretics have been determined as
their methyl derivatives by GC–MS [29, 30] and by liquid
chromatography combined with tandem mass spectrometry
(LC–MS–MS) [31–33]. The latter option does not require
derivatization and enables simplified sample preparation
because of to the compatibility of aqueous samples with the
analytical system. Figure 3 gives the structures and names
of the thiazide diuretics involved in this study. Narcotics
and stimulants can be misused in sports and are therefore
regarded as doping agents by WADAwith MRPL values of
200 ng mL−1 for narcotics and 500 ng mL−1 for stimulants.
Narcotics and stimulants have been analysed in urine using
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GC–MS [34], often in combination with solid-phase micro
extraction (SPME) [35, 36], and, incidentally, using LC–
MS–MS [37]. In this study only a few narcotics and
stimulants are considered and their structures and names are
given in Fig. 4. Doping analysis has to comply with the
requirements of International Standards for Laboratories
established by WADA, including a chain of custody,
validation of screening and confirmation methods, and
criteria for identification [38]. Therefore, newly developed
methods have to be validated before they can be used in
official control studies to demonstrate that the specific
requirements are met by the analytical method. The WADA
international standard for laboratories describes which
method performance data should be determined, however,
without stating a procedure for their determination. In this
study a validation procedure is used based on EC
commission decision 2002/657/EC, as used by many EU
laboratories involved in residue analysis in food [39].
Materials and methods
All steroid reference substances were obtained from RIVM
(Bilthoven, The Netherlands), Sigma (Zwijndrecht, The
Netherlands), or Steraloids (Rhode Island, USA). Fluocorto-
lone, the thiazide diuretics, and the narcotics and stimulants
Fig. 1 (Cortico)steroids involved in this study: budesonide (a),
prednisolone (b), prednisone (c), desonide (d), methylprednisolone
(e), cortisone (f), cortisol (g), flumethasone (h), flucortisone (i),
fluocortolone (j), fluniside (k), triamcinolone acetonide (l), dexameth-
asone (m), betamethasone (n), triamcinolone (o), gestrinone (p),
tetrahydrogestrinone (THG) (q), trenbolone (r), epitrenbolone (s)
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were a kind gift from the Doping Control Laboratory of
Athens (OAKA, Greece). All steroid substances were
obtained and handled in accordance with local legislation.
Oasis MCX cartridges were obtained from Waters (Milford,
MA, USA). All solvents were of HPLC-grade or higher.
Acetonitrile, acetone, methanol, and water were purchased
from Biosolve (Valkenswaard, The Netherlands). Sodium
acetate, sodium (bi)carbonate, and leucine-enkephalin were
purchased from Sigma. Ethyl acetate, formic acid, acetic acid
and β-glucuronidase/arylsulfatase (from Helix pomatia) were
purchased from Merck (Amsterdam, The Netherlands). All
urine samples analysed within the validation procedure were
spontaneous urine samples obtained from healthy male and
female volunteers. To account for matrix effects samples
were collected from seven volunteers resulting in a total of
21 samples for the three validation days. The samples were
Fig. 2 β2-Agonists involved in this study: clenbuterol (a), clenpro-
perol (b), clenpenterol (c), clencyclohexerol (d), brombuterol (e),
mapenterol (f), salbutamol (g), cimaterol (h), cimbuterol (i), mabuterol
(j), salmeterol (k), zilpaterol (l), carbuterol (m), terbutaline (n),
clenhexyl (o), isoxsuprine (p), procaterol (q), fenoterol (r), ractop-
amine (s), tulobuterol (t), reproterol (u), formoterol (v)
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collected in glass bottles and, after homogenization, sub-
divided into smaller PE bottles and stored at −20°C until use.
For sample preparation 3 mL urine was mixed with
2 mL sodium acetate buffer (0.25 mol L−1; pH 4.8) and
shaken. The urine samples were subsequently enzymatically
deconjugated for 1.5 h at 50°C using 25 μL β-glucuronidase/
arylsulfatase and left to cool to room temperature. An Oasis
MCX cartridge (60 mg, 3 mL) was conditioned with 3 mL
methanol followed by 3 mL sodium acetate buffer
(0.25 mol L−1; pH 4.8) before applying the deconjugated
urine samples. The cartridges were washed with 1 mL
1 mol L−1 acetic acid followed by 3 mL 15% acetone in
sodium acetate buffer (0.25 mol L−1; pH 4.8). After drying
by vacuum the compounds of interest were eluted using
3 mL 3% ammonia solution (as NH3) in ethyl acetate. The
solvent was evaporated at 40°C using a flow of nitrogen gas
Fig. 4 Narcotics and stimulants involved in this study; sydnocarb (a), oxycodone (b), phenylephrine (c), mephentermine (d), methoxyphenamine (e)
Fig. 3 Thiazide diuretics involved in this study: chlorothiazide (a), hydrochlorothiazide (b), hydroflumethiazide (c), benzthiazide (d),
bendroflumethiazide (e), althiazide (f), trichlormethiazide (g), methyclothiazide (h), cyclothiazide (i), polythiazide (j)
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until just dry and the residue was reconstituted in 200 μL
95:5 water–acetonitrile. Separation of the sample was
performed on a Waters Acquity UPLC system consisting of
a vacuum degasser, an autosampler with a cooled sample
tray, a column oven, and a binary solvent manager with
high-pressure mixing chamber. Separation was performed at
35 °C using a Waters Acquity BEH-C18 column
(100 × 2.1 mm i.d., 1.7 μm particle size). The eluents for
both positive and negative electrospray ionisation consisted
of 0.1% formic acid (A) and acetonitrile–0.1% formic acid,
9:1 (v/v) (B). Ultra pure, LC–MS-grade water from Biosolve
(Valkenswaard, The Netherlands) was used to eliminate
excessive background signals and avoid the formation of
sodium or potassium adducts. A step-wise gradient starting
at 0% B was employed at a flow of 0.4 mL min−1. From 1 to
4 min the %B was linearly increased to 40% and during 4 to
10 min linearly increased to 100% with a final hold for
2 min. The total run-to-run time (including equilibration
prior to injection of the next sample) was 13 min. The
injection volume was 20 μL.
The effluent from the UPLC system was directly
interfaced to a Bruker Daltonics micrOTOF mass spec-
trometer equipped with an orthogonal electrospray ionisa-
tion (ESI) source operated in the positive (all compounds
except thiazides) and negative (thiazides) modes using a
mass range of m/z 100 to 1000. The trigger time was 33 μs
and 10,000 spectra were summed, equalling 0.33 s time
resolution. The capillary voltage of the ion source was set at
3500 V and the capillary exit at 100 V. The nebulizer gas
pressure was 1.5 Lmin−1 and drying gas flow 8 Lmin−1.
The drying temperature was set at 200°C. Instrument
calibration was performed externally before each sequence
with a sodium formate–acetate solution using the theoret-
ical exact masses of calibration ions with formula Na
(HCO2Na)2–8 and Na(CH3CO2Na)2–8(HCO2Na)2–8 in the
range m/z 100 to 1000 for calibration. Automated post-run
internal mass scale calibration of individual samples was
performed by injecting the calibrant at the beginning and
end of each run via a six-port divert valve equipped with a
20-μL loop. The actual calibration was performed based on
calibrant injection at the beginning of the run while the
calibrant at the end of the run was for manual verification
of calibration stability. The calibrator ions in the post-run
internal mass scale calibration were the same as in the
instrument calibration.
The developed method was validated in accordance with
EU Commission Decision 2002/657/EC for a quantitative
screening method, because this includes the WADA
validation criteria and more. The validation study for the
compounds in urine was carried out at three concentrations
chosen around a validation level. This validation level (VL)
was equal to the MRPL for corticosteroids and the
threshold value for salbutamol, and to 0.5 times the MRPL
for the other β2-agonists, thiazide diuretics, narcotics, and
stimulants. The VL for the latter compound groups was set
at 0.5 times the MRPL, because it was expected that that
level could easily be determined by the LC–TOFMS
method. Blank urine samples were fortified at 0.5, 1.0,
and 2.0 times the VL level for all the target analytes and
seven replicates of each concentration were analysed on
one day. The 21 replicate analyses where repeated on two
more days resulting in 63 independent determinations.
Calibration curves were prepared from processed blank
urine samples fortified with the target analytes, before
instrumental analysis, at 0, 0.25, 0.5, 1.0, 2.0, and 4.0 times
the VL levels. Each series of fortified samples on each of
the three days started and ended with analysis of these
matrix-matched calibration standards. From the data the
repeatability, intra-laboratory reproducibility (both expressed
as the relative standard deviation, RSD), and accuracy were
calculated. The accuracy is expressed as the average
recovery from samples at the VL level relative to a processed
blank sample spiked before instrumental analysis. A range of
70–140% was considered acceptable for multi-compound
quantitative screening as in this study. The linearity was
determined for a concentration range of 0, 0.25, 0.5, 1, 2, and
4 times the VL level. On each validation day the calibration
curves were constructed and the squared regression coeffi-
cients (r2) calculated for each compound. Squared regression
coefficients >0.99 were considered acceptable. The decision
limit (CCα) and detection capability (CCβ) at the VL level
were calculated from the standard deviation at the VL level
using the following equations:
CCa ¼ VLþ 1:64 SDVL and CCb
¼ CCa þ 1:64 SDVL
Note that TOFMS is a single MS system and is,
therefore, according to EU regulation 2002/657/EC, by
definition suitable for screening analysis only. This would
exclude the determination of the decision limit CCα.
However, because the WADA validation criteria do not
pose such strict identification criteria for confirmation as
the 2002/657/EC, a value for CCα also is included in this
study. The robustness of the method was tested at the VL
level by introduction of four small but deliberate changes in
the operating procedure and by the assessment of their
effect on the method results. These deliberate changes
reflect those that may occur when a method is transferred
between different laboratories. The effect of a particular
variable was evaluated by comparison of the results from
the deliberately modified method with those from the
original method, taking into account the within-laboratory
reproducibility. The specificity and selectivity of the
method was checked by analysis of 20 representative blank
samples and by the analysis of urine samples fortified with
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approximately 200 veterinary drugs and pesticides in
addition to the target analytes at the VL level. The
chromatograms of the blank samples were monitored for
peaks that can potentially interfere with the analytes of
interest while the results from the additionally fortified
samples were compared with those from samples fortified
with the target analytes only, taking into account the within-
laboratory reproducibility. Finally, stability experiments
were carried out for all analytes. Sample extracts were
fortified at 0.5, 1.0, and 2.0 times the VL level and analysed
after storage for four weeks at −20°C. Because thiazide
diuretics in urine have been reported to be unstable because
of hydrolysis an additional experiment was carried out.
Blank urine samples were spiked with thiazide diuretics at
the VL level and analysed after storage at room temperature
for 4 and 9 days.
Results
Generic sample preparation
A generic sample-preparation method was developed that
was able to isolate and purify corticosteroids, β2-agonists,
thiazide diuretics, and some additional narcotics and
stimulants in one procedure from urine samples. The
classical sample-preparation method consists of enzymatic
hydrolysis of the urine sample using β-glucuronidase/aryl
sulfatase, followed by extraction at pH 9 with diethyl ether.
From preliminary experiments it became clear that while
this method gives good results for corticosteroids, narcotics,
and stimulants, the results for β2-agonists are poor because
of interferences by matrix constituents. Additional sample
purification was essential to eliminate these interferences
and obtain spectra of sufficient quality to determine the
correct accurate mass of the analytes of interest. However, a
typical purification step as used for β2-agonists gave poor
results for corticosteroids and thiazide diuretics, because
most are lost during the washing step with chloroform. A
combined extraction and clean-up procedure based on SPE
was tested using an Oasis MCX cartridge, which is a
polymeric mixed-mode cation-exchange–reversed-phase
sorbent enabling the retention of acidic, neutral, and,
especially, basic drugs. The SPE cartridge was conditioned
using 3 mL methanol followed by 3 mL 0.25 mol L−1
sodium acetate (pH 4.8). Samples were applied to the
cartridges, which were subsequently washed with either
3 mL water or 3 mL of an acetone–water mixture. Washing
with water generally resulted in overestimation of the β2-
agonists whereas washing with acetone–water (1:1) resulted
in losses of the β2-agonists and to a lesser extent some of
the thiazide diuretics. The alternative SPE method was
further optimized using 10%, 15%, and 20% acetone in
0.25 mol L−1 sodium acetate to wash the cartridges. Finally,
washing with 15% acetone in 0.25 mol L−1 sodium acetate
at pH 4.8 was chosen as the best compromise. The analytes
were eluted with 3 mL of an ammonia–ethyl acetate
mixture. This alternative SPE method gives reasonable
results for all compound groups.
High-resolution LC–TOFMS analysis
To develop the screening method, a solvent-based standard
with all target analytes was analyzed in positive and
negative modes. Based on the chromatographic retention
times and the specific accurate masses and the isotope
patterns calculated by the software from the elemental
composition of the target analytes, a compound database is
constructed. The isotope pattern-matching algorithm Sig-
maFit is a feature of the Bruker Daltonics micrOTOF that
can be used as an identification tool in addition to accurate
mass measurement. In the method the different combinations
of retention time and accurate masses and the acceptable
tolerances for these data and the SigmaFit value are defined.
Following analysis of a real sample the full-scan chromato-
gram is processed and the target analytes are identified using
the database and quantified using matrix-matched calibration
standards. Chromatographic separation was performed with a
C18 UPLC column and gradient elution. The repeatability of
the analytes’ retention times was acceptable and the
deviations from the expected retention times were generally
were below 1%, with individual analytes up to 3% (Table 1).
The latter was found for cortisone, an endogenous cortico-
steroid in urine with an often less symmetrical peak shape in
the chromatograms, as illustrated by the extracted ion
chromatogram (EIC) of cortisone in urine shown in Fig. 5.
Figure 5 also shows the total ion chromatograms (TIC) of a
blank urine sample (Fig. 5A), a solvent standard of the
analytes (Fig. 5B), and a blank urine sample fortified at
the 1.0 × VL level (Fig. 5C). At the beginning of the gradient
the more hydrophilic analytes such as phenylephrine and the
β2-agonist cimaterol and cimbuterol elute, while most of the
corticosteroids elute in the region of 4 to 6 min. Peak shapes
were generally good although asymmetrical peaks were
observed for phenylephrine, probably because this peak
elutes in the beginning of the gradient (Fig. 5D). For
trenbolone two distinct peaks are observed for the diaster-
eoisomers, 17β-trenbolone at 5.7 min and 17α-trenbolone at
5.9 min (Fig. 5J). Finally, the peak of tetrahydrogestrinone
(THG) is a triplet, with the first peak being THG itself and
the other two being matrix compounds that also show a
response at the accurate mass of THG (313.2162) when a
mass-tolerance window of 5 mDa is used (Fig. 5L). Even
when the mass window is set to 2 mDa these peaks are
present and only when a mass window of 1 mDa is used do
these peaks disappear. Visually these peaks originate from
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the two peaks at 7.2 and 7.3 min that are clearly visible in
TIC of the blank and the fortified urine samples in the
chromatograms in Fig. 5A and C. The negative-ion mode
data files are processed similarly and searched for the target
analytes using Brukers Target Analysis software. Figure 6
shows the negative ion mode chromatograms of the blank
urine sample (Fig. 6A), the solvent standard with all 56
added analytes (Fig. 6B), and the blank urine sample
fortified with the analytes of interest at the 1.0 × VL level
(Fig. 6C). Below, the extracted ion chromatograms of all
thiazides with the exception of bendroflumethiazide are
shown. Peaks and peak shapes are good with the exception
of cyclothiazide (Fig. 6K) that shows a double peak. The
structure of cyclothiazide shown in Fig. 3i contains four
chiral centres and therefore 16 possible isomers. However,
because of the restriction of the methylene bridgehead (cis
only) the number of stereoisomers is reduced to eight, i.e.
four diastereomeric racemates. Analysis of the standard
material showed that this contained at least two partly
separated isomers which explained the double peak. The
Fig. 5 Total ion and extracted ion chromatograms (TIC and EIC) of
urine samples and individual analytes analysed in the positive mode.
EICs of individual analytes are representative for all analytes and are
extracted using a mass window of 5 mDa. From the top down the
chromatograms shown are: TIC of a blank urine (A); TIC of a solvent
standard of the analytes (B); TIC of a blank urine fortified at the 1.0 ×
VL level (C); EIC of phenylephrine (split peak just before 3 min),
30 μg L−1 (D); EIC of cimbuterol, 50 μg L−1 (E); EIC of clenbuterol,
2 μg L−1 (F); EIC of mapenterol, 50 μg L−1 (G); EIC of cortisone,
>30 μg L−1 (H); EIC of beclomethasone, 30 μg L−1 (I); EIC of
trenbolone, 30 μg L−1 (J); EIC of gestrinone, 30 μg L−1 (K); EIC of
tetrahydrogestrinone (THG), 30 μg L−1 (L).
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results clearly show that all thiazides can be identified and
quantified at the 1.0 × VL level.
The accurate mass measurement data obtained from
spiked urine extracts are listed in Table 1. In general, for a
TOFMS having a mass resolution of ∼10,000 FWHM and
external calibration, a deviation of the measured accurate
mass from the calculated mass of 10 ppm is acceptable,
especially considering the sometimes low concentration
levels [40]. In this study the average mass accuracy for
individual compounds ranged from 1.1 to 5.8 ppm. How-
ever, for a few compounds mass measurement errors as
high as 16 ppm were observed in individual measurements.
The overall (all compounds in all measurements) average
and median mass accuracy values were 2.8 and 2.6 ppm.
These results are comparable with those of Ojanperä and
Kolmonen, who both applied the same type of Bruker
Daltonics micrOTOF system for analyses of drugs in urine
and found mean mass measurement errors of 2.5 ppm and
<5 ppm, respectively [22, 23]. The results are also
comparable with mass measurement errors found in
UPLC–TOFMS screening of veterinary drugs in food
matrices, where average values of <10 and 3.0 ppm were
Fig. 6 Total ion and extracted ion chromatograms (TIC and EIC) of
urine samples and individual analytes analysed in negative-ion mode.
EICs of individual compounds are representative for all analytes and
are extracted using a mass window of 5 mDa. From the top down the
chromatograms shown are: TIC of a blank urine (A); TIC of a solvent
standard of the analytes (B); TIC of a blank urine fortified at 1.0 × the
VL level (C); EIC of chlorothiazide, 100 μg L−1 (D); EIC of
hydrochlorothiazide, 100 μg L−1 (E); EIC of hydroflumethiazide,
100 μg L−1 (F); EIC of trichloromethiazide, 100 μg L−1 (G); EIC of
methyclothiazide, 100 μg L−1 (H); EIC of althiazide, 100 μg L−1 (I);
EIC of benzthiazide, 100 μg L−1 (J); EIC of cyclothiazide, 100 μg L−1
(K); EIC of polythiazide, 100 μg L−1 (L)
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found [10, 14]. An interesting observation is that the
average mass measurement error decreases slightly with
increasing concentration in accordance with a recent study
by Bristow, who observed an increase of the deterioration
in mass measurement accuracy at both very low and very
high ion abundances [41].
A similar relationship is expected for the SigmaFit value,
an exact numerical comparison of the theoretical and
measured isotopic patterns of a target compound. The
results indeed show that the SigmaFit value decreases with
increasing concentration. This is according to expectations,
because the signal-to-noise ratio increases with increasing
concentration resulting in a better-defined isotope pattern.
The SigmaFit value indicates the difference between
theoretical and measured isotopic patterns, and low values
(typically <0.1) indicate a good fit. This isotopic pattern
match can be used as an orthogonal identification index
together with the accurate mass and the retention time. In
this study the average SigmaFit values for individual
compounds range from 0.004 up to 0.53, and the difference
between the average (0.109) and median (0.069) value
indicates that there are only a few high SigmaFit values.
These high SigmaFit values were found for cortisone,
methylprednisolone, prednisolone, and prednisone, and to a
lesser extent for reproterol, salbutamol, carbuterol, and
cimaterol. With one exception, these compounds also show
deviations of the expected retention time and calculated
exact mass above average. For cortisone this is explained
by the fact that this compound is endogenously present at
concentrations much higher than the spiked concentrations.
For methylprednisolone, prednisolone, and prednisone the
observed deviations may be accounted for by the many
matrix compounds eluting in this part of the chromatogram,
and reproterol, carbuterol, and cimaterol elute at the
beginning of the gradient which sometimes results in
asymmetrical peak shapes. For salbutamol the reasons for
these deviations are unknown. In general however, there
seems to be a positive correlation between ΔRT, the mass
error and the SigmaFit as visualized in Fig. 7, suggesting
that co-elution of an isobaric matrix component occurs.
In-house method validation
The WADA international standard for laboratories [38]
describes which method-performance characteristics should
be determined, however, without stating a procedure for
their determination. The required performance character-
istics also depend on whether the method is intended for the
determination of “non-threshold” or “threshold” substances.
For non-threshold substances the method should be able to
identify substances in the class of prohibited substances at
the MRPL level but measurement of a concentration is not
required. Because the results for non-threshold substances
are not quantitative, criteria should be established to ensure
that a substance representative of the class of prohibited
substances can be repeatedly identified and detected as
present in the sample at the MRPL level. This criterion is
called the “identification capability” and is the same as the
CCβ value in the well known EU document 2002/657/EC
that defines and describes method validation for residue
analysis in food [39]. For threshold substances the method
should be capable of determining both, the identity and the
concentration up and around the threshold level. Taking
into account intermediate precision at the threshold level a
“decision limit” is defined which is the same as the CCα
value in the 2002/657/EC document. A good explanation of
this concept can be found in the recent WADA technical
document TD20009DL [42]. Because the WADA interna-
tional standard for laboratories does not state a procedure
for determination of the required performance data, the
procedures in the 2002/657/EC document were followed
and for reasons of clarity WADA’s identification capability
and decision limit are also abbreviated as the CCβ and
CCα values. Other validation data determined are precision/
repeatability, reproducibility, accuracy/recovery, linearity,
specificity, robustness and the stability of standards.
Table 2 presents the results for the performance
characteristics of the method. No results are shown for
cortisol and cortisone because both are endogenous com-
pounds present in urine at concentrations far higher than the
fortified concentrations and thus preventing reliable deter-
mination of the performance characteristics. There are also
no results for clenhexyl, carbuterol, procaterol, and repro-
terol, because these could be identified in a limited number
Fig. 7 Deviations in RT (ΔRT), the mass error (Δm/z) and SigmaFit
show some positive correlation
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Table 2 Prohibited substances and performance characteristics according to 2002/657/EC as determined in this study. With the exception of VL,
CCα, and CCβ, the data are expressed as the averages for the three concentrations (0.5, 1.0, and 1.5 times the VL) tested on three different days.
CCα and CCβ are calculated on the basis of 1.0 times the VL
Compound Elemental
composition
Analyte
number
VL (μgL−1)a (r2)b Accuracy (%)c rs (%)
d Rs (%)
e CCα
(μgL−1)f
CCβ
(μgL−1)g
LOQ h
Corticosteroids
Beclomethasone C22H29ClO5 1 30 0.993 106 12 14 37 44 8
Betamethasone C22H29FO5 2 30 0.995 113 8 13 37 44 4
Budesonide C25H34O6 3 30 0.999 97 12 14 36 42 4
Cortisol C21H30O5 4 30 – – – – – – –
Cortisone C21H26O5 5 30 – – – – – – –
Desonide C24H32O6 6 30 0.995 100 8 12 36 42 4
Dexamethasone C22H29FO5 7 30 0.995 113 8 13 37 44 4
Epitrenbolone C18H22O2 8 30 0.996 105 13 15 38 46 2
Fludrocortisone C21H29FO5 9 30 0.997 86 11 18 38 46 8
Flumethasone C22H28F2O5 10 30 0.995 113 15 19 41 51 8
Flunisolide C24H31FO6 11 30 0.992 101 11 17 39 47 4
Fluocortolone C22H29FO4 12 30 0.978 101 12 15 38 45 8
Gestrinone C21H24O2 13 30 0.999 94 13 16 36 42 8
Methylprednisolone C22H30O5 14 30 0.994 101 8 13 36 42 8
Prednisolone C21H26O5 15 30 0.998 99 14 14 37 44 8
Prednisone C21H26O5 16 30 0.995 96 9 12 36 42 8
Tetrahydrogestrinone C21H28O2 17 30 0.998 97 16 20 40 49 15
Trenbolone C18H22O2 18 30 0.997 96 13 16 37 45 8
Triamcinolone C21H27FO6 19 30 0.997 97 7 17 38 47 8
Triamcinolone -acetonide C24H31FO6 20 30 0.996 94 9 11 35 40 4
β2-agonists
Bromobuterol C12H18Br2N2O 21 50 0.990 117 13 23 72 94 1
Carbuterol C13H21N3O3 22 50 0.992 143 33 115 192 334 50
Cimaterol C12H17N3O 23 50 0.995 95 15 29 80 109 7
Cimbuterol C13H19N3O 24 50 0.996 93 9 21 66 81 2
Clenbuterol C12H18Cl2N2O 25 2 0.994 98 12 14 2.5 2.9 0.5
Clencyclohexerol C14H20Cl2N2O2 26 50 0.996 82 13 28 69 87 2
Clenhexyl C14H21Cl2N2O 27 50 – – – – – – –
Clenpenterol C13H20Cl2N2O 28 50 0.997 68 42 77 96 143 16
Clenproperol C11H16Cl2N2O 29 50 0.993 112 10 13 62 74 4
Fenoterol C17H21NO4 30 50 0.993 110 12 16 64 78 13
Formoterol C19H24N2O4 31 50 0.996 91 14 25 69 88 4
Isoxsuprine C18H23NO3 32 50 0.991 113 11 13 62 74 2
Mabuterol C13H18ClF3N2O 33 50 0.994 106 10 14 62 74 2
Mapenterol C14H20ClF3N2O 34 50 0.994 109 11 13 62 73 1
Procaterol C16H22N2O3 35 50 – – – – – – –
Ractopamine C18H23NO3 36 50 0.991 101 8 23 77 104 4
Reproterol C18H23N5O5 37 50 – – – – – – –
Salbutamol C13H21NO3 38 50 0.993 89 14 39 91 133 7
Salmeterol C25H37NO4 39 50 0.965 111 24 67 109 168 7
Terbutaline C12H19NO3 40 50 0.996 88 10 20 64 78 15
Tulobuterol C12H18ClNO 41 50 0.993 130 13 20 71 92 2
Zilpaterol C14H19N3O2 42 50 0.989 73 25 42 75 100 2
Narcotics/stimulants
Mephentermine C11H17N 43 30 0.990 93 27 38 62 94 4
2 Prohibited substances and performance chara teristics
accordi g to 2002/657/EC as determined in this tudy. With the
exception of VL, CCα, and CCβ, the data are expressed as the
averages for the three conc ntration (0.5, 1.0, and 1.5 times the )
tested on three different days. CCα and CCβ are calculated on the
basis of 1.0 times the VL
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of samples only, not enabling us to calculate a reliable value
for the performance characteristics. For all other com-
pounds in this study the results in Table 2 show that the
repeatability of the method ranges from 7 to 42% with an
average value of 14%, and for 90% of the compounds the
repeatability is <20%. The poorest repeatability is found for
clenpenterol (42%) and zilpaterol (25%) as a result of
limited sensitivity, and matrix interference. The intra-
laboratory reproducibility ranges from 11 to 77% with an
average value of 21%. The median value of 17% indicates
that there are only a few poor reproducibility values and, as
mentioned before, these are clenpenterol (77%) and
zilpaterol (42%), but also salmeterol (67%). For 70% of
the components the reproducibility is still <20%. In this
study the validation level for the β2-agonists (and thiazide
diuretics, narcotics, and stimulants) was set at 0.5 times the
MRPL. As a consequence the actual repeatability and
reproducibility at the MRPL level will most likely be better
than the values presented in Table 2. The accuracy for the
compounds in this study ranges from 68 to 143% with an
average of 102% and a median value of 100% indicating a
uniform distribution. The lowest accuracy was found for
clenpenterol and the highest was found for carbuterol. In
general it can be noticed that the accuracy for the individual
corticosteroids, narcotics, and stimulants, and thiazide
diuretics, are similar. On the other hand, much wider
distribution is found for the accuracy of the individual β2-
agonists which is explained by the washing step of the SPE
column. Although a 15% acetone solution was finally
selected it is clear that this remains a compromise that gives
the best overall performance but results in individual
differences. However, because the accuracy for 54 of the
56 compounds is in the range 70 to 140% we conclude that
the method is capable of producing accurate screening
results for all of the analytes with the exception of
carbuterol and clenpenterol. The squared regression coeffi-
cient (r2) is used to evaluate the linearity and is presented in
Table 2. The matrix-matched calibration curves show r2 >
0.99 for 90% of the analytes with exceptions for fluocorto-
lone, salmeterol, and bendroflumethiazide. Although no
limit of quantitation (LOQ) is actually determined, an
indication of its value is estimated from the lowest
calibration standard and is given in Table 2. The LOQ
values range from 0.5 μg L−1 for compounds for which
sensitivity is high, for example clenbuterol, to over
50 μg L−1 for compounds for which sensitivity is low, for
Table 2 (continued)
Compound Elemental
composition
Analyte
number
VL (μgL−1)a (r2)b Accuracy (%)c rs (%)
d Rs (%)
e CCα
(μgL−1)f
CCβ
(μgL−1)g
LOQ h
Methoxyphenamine C11H17NO 44 30 0.993 133 17 30 53 76 1
Oxycodone C18H21NO4 45 30 0.997 100 17 25 42 54 1
Phenylephrine C9H13NO2 46 30 0.995 116 15 22 42 55 15
Sydnocarb C18H18N4O2 47 30 0.994 84 20 26 41 52 8
Thiazide diuretics
Althiazide C11H14ClN3O4S3 48 100 0.994 91 11 11 117 133 25
Bendroflumethiazide C15H14F3N3O4S2 49 100 0.984 135 14 19 142 185 5
Benzthiazide C15H14ClN3O4S3 50 100 0.997 118 15 22 144 187 7
Chlorothiazide C7H6ClN3O4S2 51 100 0.993 104 15 16 127 153 4
Cyclothiazide C14H16ClN3O4S2 52 100 0.996 109 12 14 125 150 7
Hydrochlorothiazide C7H8ClN3O4S2 53 100 0.994 90 14 17 125 151 7
Hydroflumethiazide C8H8F3N3O4S2 54 100 0.994 103 13 17 128 156 4
Methyclothiazide C9H11Cl2N3O4S2 55 100 0.996 111 9 15 128 155 7
Polythiazide C11H13ClF3N3O4S3 56 100 0.975 121 15 17 133 166 2
Trichloromethiazide C8H8Cl3N3O4S2 57 100 0.998 97 15 16 126 153 25
a VL: The validation level is the concentration added to samples (μg L−1 ); validation was carried out at 0.5, 1.0, and 2.0 times the VL
b r2 : Squared regression coefficient
c Accuracy, the recovery of the spiked analyte expressed as a percentage (and corrected for matrix suppression)
d Repeatability expressed as the relative standard deviation in seven analyses performed on one day
eWithin-lab reproducibility expressed as the relative standard deviation in three series of seven analyses performed on three days by different
analysts
f CCα: Decision limit calculated from the within-lab reproducibility at the validation level 1.0 times the VL
g CCβ: Detection capability calculated from the within-lab reproducibility at the validation level 1.0 times the VL
h LOQ: Limit of quantitation estimated from the lowest calibration standard
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example carbuterol. With the exception of clenhexyl,
procaterol, and reproterol all LOQs enable determination
of compound concentrations at the MRPL level. CCα and
CCβ values are calculated from the within laboratory
reproducibility at the level of interest, e.g. 1.0 × VL. As a
consequence, CCα and CCβ values are always higher than
the validation level at which they are determined. The CCα
and CCβ values for the analytes in this study are included
in Table 2. In general, for 90% of the analytes the CCα and
CCβ values are within a factor of 2 of the VL level at
which they were determined. Typical exceptions are
carbuterol, clenpenterol, and salmeterol, all belonging to
the β-agonist group. Only for salmeterol and, especially,
carbuterol is CCα more than a factor of 2 higher than the
corresponding VL level.
The robustness of the method was tested by analyzing
three identical urine samples fortified at 0.5, 1.0, and 2.0 ×
VL using the developed procedure with two small
deliberate changes in the operating procedure. For the first
set of three samples the usual procedure was followed
whereas for the second set of samples the SPE column was
run dry for 10 min after application of the aqueous extract
and before the wash step. For the third set of samples the
final residue after evaporation of the solvent was left dry for
30 min before re-dissolving. The results at each VL level
were determined and if these were within 3 times the
previously determined reproducibility for the original
method then the method was regarded as robust. The
selectivity of the method is the ability to discriminate
between the analyte, the matrix, and any chemical or
instrumental noise and was determined by analysis of 20
blank urine samples. The chromatograms obtained from the
blank samples were monitored for the analytes of interest.
Because no peaks (>LOQ or >3 times the repeatability)
were detected in these blank samples except for endogenous
compounds, it is concluded that the method is selective. The
specificity of the method is the ability to discriminate between
the analytes of interest and other related substances that may
be isomers, metabolites, or degradation products, or other
small molecules that may be present in the matrix. To test the
method’s specificity urine samples were fortified with
approximately 200 veterinary drugs and pesticides in addition
to the target analytes at 0.5, 1.0, and 2.0 × the VL. The
chromatograms were monitored for peaks that can potentially
interfere with the analytes of interest and the results compared
with those obtained from samples fortified with only the target
analytes and taking into account the reproducibility of the
method. Because the results for urine samples fortified with
additional compounds were within 3 times the reproducibility
of the method, the method is regarded as specific. Even in the
region were cortisol and cortisone elute, determination of
other analytes at 0.5× the VL level is not hampered by the
often higher cortisol/cortisone concentrations. Finally, stabil-
ity experiments were carried out for all compounds in extracts
stored at −20°C and for thiazide diuretics in urine at room
temperature. Analyses of sample extracts fortified at 0.5, 1.0,
and 2.0 times the VL level and stored for four weeks at −20°C
showed that all the analytes were stable during this period.
Recovery at the three VL levels ranged from 65 to 147% with
average values of 94±22%, 101±18%, and 109±16% at the
three VL levels. Methylprednisolone was an exception,
because recovery was below 80% at all three VL levels.
Because thiazide diuretics are reported to be unstable in urine,
because of hydrolysis, an additional stability experiment was
performed [43]. Blank urine samples were spiked with
thiazide diuretics at the VL level and analysed after storage
for 1, 4, and 9 days at room temperature. The results show
that althiazide, especially, and bendroflumethiazide and
cyclothiazide are not stable at room temperature for
prolonged periods. For these compounds, average recoveries
after 4 and 9 days at room temperature were 60% and 10%,
respectively. For the other thiazides the average recoveries
after 4 and 9 days were 80% and 60%, respectively.
Conclusions
A generic sample-preparation procedure was combined
with solid-phase extraction tailored for the simultaneous
isolation and purification of glucocorticosteroids, β2-
agonists, thiazide diuretics, and narcotics and stimulants in
urine. All compounds are determined using high-resolution
liquid chromatography in combination with time-of-flight
mass spectrometry using positive electrospray ionisation.
However, for the best sensitivity and quantitative determi-
nation the thiazide diuretics are best analysed using
negative electrospray ionisation. The results show that with
the exception of the β2-agonists clenhexyl, procaterol, and
reproterol all compounds can be detected below the
respective MRPL values. The results for linearity, repeat-
ability, within-lab reproducibility, and accuracy show that
the method is capable of quantitative screening for >90% of
the individual compounds. Notable exceptions are clenpen-
terol, zilpaterol, and salmeterol for which repeatability and
reproducibility were >20% and clenpenterol and carbuterol
for which the accuracy was just outside the 70–140%
acceptability window. If qualitative screening is sufficient
instrumental analysis can be limited to positive electrospray
ionisation, because all the analytes including the thiazides
can be detected at the respective MRPL levels in positive-ion
mode. The results show that application of high-resolution
liquid chromatography–time-of-flight mass spectrometry in
combination with general extraction and purification proce-
dures is suitable for unification of screening procedures for
prohibited small-molecule substances.Moreover, the full-scan
accurate-mass data sets obtained still enable retrospective
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examination for emerging doping agents, without re-analysis
of the samples. These benefits should allow doping control
laboratories to free resources for new classes of banned
substances.
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